Who is sponsoring NCT07202039?

NCT07202039 is sponsored by Prisma Health-Upstate.

What drugs are being tested in NCT07202039?

Interventions in NCT07202039: Brief individual counseling sessions.

What condition does NCT07202039 study?

NCT07202039 studies Tobacco-flavored EC, Sweet-Cooling EC, Sweet Non-cooling EC.

Is NCT07202039 still recruiting?

NCT07202039 is currently not yet recruiting. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT07202039: SWITCH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine

Not yet recruiting NA Last updated 16 April 2026

What this trial tests

NA trial testing Brief individual counseling sessions in Tobacco-flavored EC in 90 participants. Not yet recruiting.

Timeline

29 April 2026

Primary endpoint
30 March 2029

29 June 2029

Quick facts

Lead sponsor	Prisma Health-Upstate
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	29 April 2026
Primary completion	30 March 2029
Estimated completion	29 June 2029
Sites	1 location across United States

Drugs / interventions tested

Brief individual counseling sessions

Conditions studied

Tobacco-flavored EC — all drugs for Tobacco-flavored EC →
Sweet-Cooling EC — all drugs for Sweet-Cooling EC →
Sweet Non-cooling EC — all drugs for Sweet Non-cooling EC →

Sponsor

Prisma Health-Upstate — full company profile →

Who can join

21 and older, any sex, with Tobacco-flavored EC or Sweet-Cooling EC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Prisma Health-Upstate trials

Trials by the same sponsor.

NCT07375212 — VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure · Phase 4 · withdrawn
NCT07102615 — Intracervical Vasopressin · Phase 4 · recruiting
NCT07101250 — Preoperative Acetazolamide · Phase 4 · recruiting
NCT06874413 — Targeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Vent · NA · enrolling by invitation
NCT06907693 — The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07202039 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prisma Health-Upstate
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07202039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing